Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma

| December 12, 2017 | 0 Comments
Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma

The FDA has granted accelerated approval to acalabrutinib (Calquence®) for the treatment of adults with mantle cell lymphoma whose cancer has progressed after receiving at least one prior therapy.
See Original Article

Category: Recent News

About the Author ()

Leave a Reply